This is a preview of subscription content, log in via an institution to check access.
References
Clift RA, Appelbaum FR, Thomas ED: Treatment of chronic myeloid leukemia by marrow transplantation. Blood 1993; 82: 1954–1956.
Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Bone Marrow Transplantation Working Party Chronic Leukemia. Blood 1995; 86: 2041–2050.
Coleman S, Throp D, Fisher J, Bailey-Wood R, Lim SH . Cytokine enhancement of immunogenecity in chronic myeloid leukemia. Leukemia 1997; 11: 2055–2059.
Clark RE, Dody IA, Hill SC, Lill JR, Aubert G, Macintyre AR et al. Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood 2001; 98: 2887–2893.
Cella M, Sallusto F, Lanzavecchia A . Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol 1997; 9: 10–16.
Choudhury A, Gajewski JL, Liang JC, Popat U, Claxton DF, Kliche K-O et al. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against philadelphia chromosome-positive chronic myelogenous leukemia. Blood 1997; 89: 1133–1142.
Vermorken JB, Claessen AME, van Tinteren H, Gall HE, Ezinga R, Meijer S et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 1999; 353: 345–350.
Vuylsteke R JCLM, van Leeuwen PAM, Meijer S, Wijnands PG, Statius Muller MG, Bus DH et al. A novel method of sampling tumor draining lymph nodes for phenotypic and functional analysis of dendritic cells and T-cells. Am J Pathol 2002; 61: 19–26.
de Gruijl TD, Bontkes HJ, Walboomers JMM, Stukart MJ, Robbesom AA, vonBlomberg-van der Flier BM et al. Analysis of IgG reactivity against human papillomavirus type-16 E7 in patients with cervical intraepithelial neoplasia indicates an association with clearance of viral infection: results of a prospective study. Int J Cancer 1996; 731: 731–738.
Druker BJ, Talpaz M, Resta D, Resta DJ, Peng B, Buchdunger E et al. Activity and safety of a specific inhibitor of the BCR-ABL tyrosine-kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1038–1042.
Weisberg E, Griffin JD . Mechanism of resistance to the ABL tyrosine-kinase inhibitor STI571 in BCR-ABL transformed hematopoietic cell lines. Blood 2000; 95: 3498–3505.
Tipping AJ, Mahon FX, Zafirides G, Lagarde V, Goldman JM, Melo JV . Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs. Leukemia 2002; 16: 2349–2357.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ossenkoppele, G., Stam, A., Westers, T. et al. Vaccination of chronic myeloid leukemia patients with autologous in vitro cultured leukemic dendritic cells. Leukemia 17, 1424–1426 (2003). https://doi.org/10.1038/sj.leu.2402979
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2402979
- Springer Nature Limited
This article is cited by
-
Haematological malignancies: at the forefront of immunotherapeutic innovation
Nature Reviews Cancer (2015)
-
Induction of high-titer IgG antibodies against multiple leukemia-associated antigens in CML patients with clinical responses to K562/GVAX immunotherapy
Blood Cancer Journal (2013)
-
Tumour antigen-targeted immunotherapy for chronic myeloid leukaemia: is it still viable?
Cancer Immunology, Immunotherapy (2009)
-
Maintained immunogenicity of chronic myeloid leukemia-derived dendritic cells in the presence of Imatinib mesylate: implication for vaccination regimens
Leukemia (2006)
-
Targeting the silent minority: emerging immunotherapeutic strategies for eradication of malignant stem cells in chronic myeloid leukaemia
Cancer Immunology, Immunotherapy (2005)